Cargando…
Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834747/ https://www.ncbi.nlm.nih.gov/pubmed/33387615 http://dx.doi.org/10.1016/j.anai.2020.12.014 |
| _version_ | 1783642353409458176 |
|---|---|
| author | Hartog, Nicholas L. Davis, Alan T. Prokop, Jeremy W. Walls, Andrew Rajasekaran, Surender |
| author_facet | Hartog, Nicholas L. Davis, Alan T. Prokop, Jeremy W. Walls, Andrew Rajasekaran, Surender |
| author_sort | Hartog, Nicholas L. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7834747 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78347472021-01-26 Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab Hartog, Nicholas L. Davis, Alan T. Prokop, Jeremy W. Walls, Andrew Rajasekaran, Surender Ann Allergy Asthma Immunol Letter American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021-03 2020-12-30 /pmc/articles/PMC7834747/ /pubmed/33387615 http://dx.doi.org/10.1016/j.anai.2020.12.014 Text en © 2020 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter Hartog, Nicholas L. Davis, Alan T. Prokop, Jeremy W. Walls, Andrew Rajasekaran, Surender Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title | Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title_full | Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title_fullStr | Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title_full_unstemmed | Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title_short | Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| title_sort | monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834747/ https://www.ncbi.nlm.nih.gov/pubmed/33387615 http://dx.doi.org/10.1016/j.anai.2020.12.014 |
| work_keys_str_mv | AT hartognicholasl monitoringneutrophiltolymphocyteratioinpatientswithcoronavirusdisease2019receivingtocilizumab AT davisalant monitoringneutrophiltolymphocyteratioinpatientswithcoronavirusdisease2019receivingtocilizumab AT prokopjeremyw monitoringneutrophiltolymphocyteratioinpatientswithcoronavirusdisease2019receivingtocilizumab AT wallsandrew monitoringneutrophiltolymphocyteratioinpatientswithcoronavirusdisease2019receivingtocilizumab AT rajasekaransurender monitoringneutrophiltolymphocyteratioinpatientswithcoronavirusdisease2019receivingtocilizumab |